# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2021 Earnings Results

**Report date:** 2021-08-05 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2021

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.7%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $25.80 | N/A | +192.85% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Management expressed confidence in the company's performance and future prospects. They highlighted the strong EPS as a result of effective strategies.

**Key quotes:**

> The strong EPS reflects our continued focus on innovation and operational efficiency.

> We are excited about our pipeline and the potential for future growth.

### Guidance Changes

No guidance data was provided for future quarters.

### What It Means

Regeneron's strong EPS performance significantly exceeded expectations, leading to a 3.7% increase in stock price. This positive reaction indicates investor confidence in the company's ongoing strategies and future growth potential. However, the lack of revenue data and guidance leaves some uncertainty about overall performance moving forward.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2021_